Early treatment failure during treatment of Plasmodium falciparum malaria with atovaquone-proguanil in the Republic of Ivory Coast

Malaria Journal

Volumn 11, Issue , 2012, Pages

  Wurtz, Nathalie ^a,b   Pascual, Aurélie ^a,b   Marin Jauffre, Adeline ^a   Bouchiba, Housem ^a   Benoit, Nicolas ^b,c   Desbordes, Marc ^b,c   Martelloni, Maryse ^b,c   De Santi, Vincent Pommier ^d   Richa, Georges ^e   Taudon, Nicolas ^b,c   Pradines, Bruno ^a,b   Briolant, Sébastien ^a  

^a INSTITUT DE RECHERCHE BIOMÉDICALE DES ARMÉES   (France)

^b Centre National de Reference du Paludisme   (France)

^c Aix Marseilles University   (France)

^d Centre d Epidémiologie et de Santé Publique des Armées   (France)

^e Centre Médical des Armées de Nîmes Orange Laudun Antenne Vétérinaire de Nîmes   (France)

Author keywords

Anti malarial drug; Atovaquone proguanil; Clinical failure; Cytochrome b; in vitro; Malaria; Malarone; Plasmodium falciparum; Resistance

Indexed keywords

ATOVAQUONE PLUS PROGUANIL; DOXYCYCLINE; PARACETAMOL; QUINIMAX;

ADULT; ARTICLE; BLOOD SMEAR; CASE REPORT; COTE D'IVOIRE; CYTOCHROME B GENE; DRUG BIOAVAILABILITY; DRUG TREATMENT FAILURE; GENE; HUMAN; MALARIA FALCIPARUM; SOLDIER;

ANTIMALARIALS; ATOVAQUONE; COTE D'IVOIRE; CYTOCHROMES B; DRUG COMBINATIONS; HUMANS; MALARIA, FALCIPARUM; MALE; MIDDLE AGED; PLASMODIUM FALCIPARUM; PROGUANIL; TREATMENT FAILURE;

EID: 84860343744     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-11-146     Document Type: Article

References (37)

1. Atovaquone-proguanil: report from the CDC expert meeting on malaria chemoprophylaxis (II). Boggild AK, Parise ME, Lewis LS, Kain KC, AmJTrop Med Hyg 2007 76 208 223 (Pubitemid 351627765)
2. Atovaquone-proguanil for the prophylaxis and treatment of malaria. Patel SN, Kain KC, Expert Rev Anti Infect Ther 2005 3 849 861 10.1586/14787210.3.6.849 16307498 (Pubitemid 41782586)
3. A systematic review and meta-analysis of the effectiveness and safety of atovaquone-proguanil (Malarone) for chemoprophylaxis against malaria. Nakato H, Vivancos R, Hunter PR, J Antimicrob Chemother 2007 60 929 936 10.1093/jac/dkm337 17848375 (Pubitemid 47617737)
4. Malarone (atovaquoneproguanil hydrochloride): a review of its clinical development for treatment of malaria. Looareesuwan S, Chulay JD, Canfield CJ, Hutchinson DB, Malarone Clinical Trials Study Group. Am J Trop Med Hyg 1999 60 533 541 (Pubitemid 29233107)
5. Atovaquone-proguanil for treating uncomplicated malaria. Osei-Akoto A, Orton L, Owusu-Ofori SP, Cochrane Database Syst Rev 2005 2005 CD004529
6. Atovaquone-proguanil treatment failure in Plasmodium falciparum. Contentin L, Grammatico-Guillon L, Desoubeaux G, Baron S, Thanh HD, Presse Med 2011 40 1081 1083 10.1016/j.lpm.2011.03.009 21570798
7. Plasmodium falciparum malaria and atovaquone-proguanil treatment failure. Durand R, Prendki V, Cailhol J, Hubert V, Ralaimazava P, Massias L, Bouchaud O, Le Bras J, Emerg Infect Dis 2008 14 320 322 10.3201/eid1402.070945 18258131 (Pubitemid 351213688)
8. Evidence of Plasmodium falciparum malaria resistant to atovaquoneproguanil hydrochloride: case reports. Farnert A, Lindberg J, Gil P, Swedberg G, Berqvist Y, Thapar MM, Lindegardh N, Berezcky S, Bjorkman A, BMJ 2003 326 628 629 10.1136/bmj.326.7390.628 12649236 (Pubitemid 36363571)
9. Malarone treatment failure and in vitro confirmation of resistance of Plasmodium falciparum isolate from Lagos. Fivelman QL, Butcher GA, Adagu IS, Warhurst DC, Pasvol G, Nigeria. Malar J 2002 1 1
10. Emergence of atovaquone-proguanil resistance during treatment of Plasmodium falciparum malaria acquired by a non-immune north American traveller to west Africa. Kuhn S, Gill MJ, Kain KC, AmJTrop Med Hyg 2005 72 407 409 (Pubitemid 41278848)
11. Atovaquone-proguanil resistance in imported falciparum malaria in a young child. Rose GW, Suh KN, Kain KC, Le Saux N, McCarthy AE, Pediatr Infect Dis J 2008 27 567 569 10.1097/INF.0b013e318167918d 18434932
12. Genetic confirmation of atovaquone-proguanil-resistant Plasmodium falciparum malaria acquired by a nonimmune traveler to East Africa. Schwartz E, Bujanover S, Kain KC, Clin Infect Dis 2003 37 450 451 10.1086/375599 12884171 (Pubitemid 36976505)
13. Malarone treatment failure not associated with previously described mutations in the cytochrome b gene. Wichmann O, Muehlen M, Gruss H, Mockenhaupt FP, Suttorp N, Jelinek T, Malar J 2004 3 14 10.1186/1475-2875-3-14 15186499 (Pubitemid 39319759)
14. Atorvastatin as a potential antimalarial drug: in vitro synergy in combinational therapy with dihydroartemisinin. Savini H, Souraud JB, Briolant S, Baret E, Amalvict R, Rogier C, Pradines B, Antimicrob Agents Chemother 2008 54 966 967
15. Antimalarial drug susceptibility and point mutations associated with drug resistance in 248 Plasmodium falciparum isolates imported from Comoros to Marseille, France in 2004 2006. Parola P, Pradines B, Simon F, Carlotti MP, Minodier P, Ranjeva MP, Badiaga S, Bertaux L, Delmont J, Morillon M, Silai R, Brouqui P, Parzy D, AmJTrop Med Hyg 2007 77 431 437 (Pubitemid 351844314)
16. WHO, Evaluation et surveillance de lefficacité des antipaludiques pour le traitement du paludisme Plasmodium falciparum non compliqué World Health Organization, Geneva 2004 Report No.: WHO/HTM/RBM/2003.50 21440569
17. Vivax malaria in Mauritania includes infection of a Duffy-negative individual. Wurtz N, Mint Lekweiry K, Bogreau H, Pradines B, Rogier C, Ould Mohamed Salem Boukhary A, Hafid JE, Ould Ahmedou Salem MS, Trape JF, Basco LK, Briolant S, Malar J 2011 10 336 10.1186/1475-2875-10-336 22050867
18. Clinical atovaquone-proguanil resistance of Plasmodium falciparum associated with cytochrome b codon 268 mutations. Musset L, Bouchaud O, Matheron S, Massias L, Le Bras J, Microbes Infect 2006 8 2599 2604 10.1016/j.micinf. 2006.07.011 16962361 (Pubitemid 44604457)
19. La résistance aux antipaludiques. Pradines B, Dormoire J, Briolant S, Bogreau H, Rogier C, Rev Fr Lab 2010 422 51 62
20. Susceptibility of Plasmodium falciparum isolates to doxycycline is associated with pftetQ sequence polymorphisms and pftetQ and pfmdt copy numbers. Briolant S, Wurtz N, Zettor A, Rogier C, Pradines B, J Infect Dis 2010 201 153 159 10.1086/648594 19929377
21. Plasmodium falciparum Na+/H+ exchanger 1 transporter is involved in reduced susceptibility to quinine. Henry M, Briolant S, Zettor A, Pelleau S, Baragatti M, Baret E, Mosnier J, Amalvict R, Fusai T, Rogier C, Pradines B, Antimicrob Agents Chemother 2009 53 1926 1930 10.1128/AAC.01243-08 19273668
22. Synergy of mefloquine activity with atorvastatin, but not chloroquine and monodesethylamodiaquine, and association with the pfmdr1 gene. Wurtz N, Briolant S, Gil M, Parquet V, Henry M, Baret E, Amalvict R, Almeras L, Rogier C, Pradines B, J Antimicrob Chemother 2010 65 1387 1394 10.1093/jac/dkq173 20501488
23. Genetic diversity and structure of African Plasmodium falciparum populations in urban and rural areas. Bogreau H, Renaud F, Bouchiba H, Durand P, Assi SB, Henry MC, Garnotel E, Pradines B, Fusai T, Wade B, Adehossi E, Parola P, Kamil MA, Puijalon O, Rogier C, AmJTrop Med Hyg 2006 74 953 959 (Pubitemid 351627399)
24. Possible autochthonous malaria from Marseille to Minneapolis. Doudier B, Bogreau H, DeVries A, Poncon N, Stauffer WM, Fontenille D, Rogier C, Parola P, Emerg Infect Dis 2007 13 1236 1238 10.3201/eid1308.070143 17953101 (Pubitemid 47359174)
25. Molecular analysis of two local falciparum malaria outbreaks on the French Guiana Coast confirms the msp1 B-K1/varD genotype association with severe malaria. Legrand E, Volney B, Lavergne A, Tournegros C, Florent L, Accrombessi D, Guillotte M, Mercereau-Puijalon O, Esterre P, Malar J 2005 4 26 10.1186/1475-2875-4-26 15969766 (Pubitemid 41185381)
26. Cytochrome b mutations that modify the ubiquinol-binding pocket of the cytochrome bc1 complex and confer anti-malarial drug resistance in Saccharomyces cerevisiae. Kessl JJ, Ha KH, Merritt AK, Lange BB, Hill P, Meunier B, Meshnick SR, Trumpower BL, J Biol Chem 2005 280 17142 17148 10.1074/jbc.M500388200 15718226 (Pubitemid 41389179)
27. Atovaquone, a broad spectrum antiparasitic drug, collapses mitochondrial membrane potential in a malarial parasite. Srivastava IK, Rottenberg H, Vaidya AB, J Biol Chem 1997 272 3961 3966 10.1074/jbc.272.7.3961 9020100 (Pubitemid 27078454)
28. A mechanism for the synergistic antimalarial action of atovaquoneproguanil. Srivastava IK, Vaidya AB, Antimicrob Agents Chemother 1999 43 1334 1339 10348748 (Pubitemid 29259321)
29. Atovaquone resistance in malaria parasites. Vaidya AB, Mather MW, Drug Resist Updat 2000 3 283 287 10.1054/drup.2000.0157 11498396
30. GlaxoSmithKlineInc, Malarone. GSK Product Monograph Research Triangle Park GSK, NC 2004
31. Population pharmacokinetics of proguanil in patients with acute P. falciparum malaria after combined therapy with atovaquone. Hussein Z, Eaves CJ, Hutchinson DB, Canfield CJ, Br J Clin Pharmacol 1996 42 589 597 8951190
32. A randomized, double-blind, placebo-controlled field trial to determine the efficacy and safety of Malarone (atovaquone-proguanil) for the prophylaxis of malaria in Zambia. Sukwa TY, Mulenga M, Chisdaka N, Roskell NS, Scott TR, AmJTrop Med Hyg 1999 60 521 525 (Pubitemid 29233105)
33. Population pharmacokinetics of atovaquone in patients with acute malaria caused by Plasmodium falciparum. Hussein Z, Eaves J, Hutchinson DB, Canfield CJ, Clin Pharmacol Ther 1997 61 518 530 10.1016/S0009-9236(97)90132-6 9164414 (Pubitemid 27261756)
34. Sex affects the steady-state pharmacokinetics of primaquine but not doxycycline in healthy subjects. Binh VQ, Chinh NT, Thanh NX, Cuong BT, Quang NN, Dai B, Travers T, Edstein MD, AmJTrop Med Hyg 2009 81 747 753
35. Pharmacokinetics and bioequivalence study of doxycycline capsules in healthy male subjects. Gschwend MH, Martin W, Erenmemisoglu A, Scherm M, Dilger C, Tamur U, Kanzik I, Hincal AA, Arzneimittelforschung 2007 57 347 351 17688080 (Pubitemid 47056003)
36. WHO, Susceptibility of Plasmodium falciparum to antimalarial drugs. Report on global monitoring: 1996-2004 World Health Organization, Geneva 2005 Report No.: WHO/HTM/MAL/2005.1103
37. Why is it that antimalarial drug treatments do not always work? White NJ, Ann Trop Med Parasitol 1998 92 449 458 10.1080/00034989859429 9683896 (Pubitemid 28312560)